Search

Displaying results 2571 - 2580 of 5506 in total
  1. Drug

    AN-9

    go.drugbank.com/drugs/DB05103
    Investigational

    It shows greater potency than BA at inducing malignant cell differentiation and tumor growth inhibition and has demonstrated more favorable toxicological, pharmacological, and pharmaceutical properties

  2. Drug

    Alglucerase

    go.drugbank.com/drugs/DB00088
    ApprovedWithdrawn

    Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market. … The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues.

  3. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. Bruton's tyrosine kinase plays a role in B cell r...

  4. Drug

    Squalene

    go.drugbank.com/drugs/DB11460
    ApprovedInvestigationalVet approvedWithdrawn

    It is a natural 30-carbon isoprenoid compound and intermediate metabolite in the synthesis of cholesterol. It is not susceptible to lipid peroxidation and provides skin protection. … It is ubiquitously distributed in human tissues where it is transported in serum generally in association with very low density lipoproteins. Squalene is investigated as an adjunctive cancer therapy.

    Synonyms: (E,E,E,E)-Squalene, (all-E)-2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene
  5. Drug

    Viral Macrophage-Inflammatory Protein

    go.drugbank.com/drugs/DB15748
    Experimental

    It helps its virus evade the host immune system through selectively blocking and activating different receptors, preferentially inhibiting acute Th1-associated inflammation while also upregulating Th2

  6. Drug

    AP5346

    go.drugbank.com/drugs/DB04992
    Investigational

    It is being pursued by Access Pharmaceuticals, Inc. … AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer.

  7. Drug

    Revefenacin

    go.drugbank.com/drugs/DB11855
    ApprovedInvestigational

    [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]

  8. Drug

    Streptomycin

    go.drugbank.com/drugs/DB01082
    ApprovedInvestigationalVet approved

    [A233325,A232294] Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as

  9. Drug

    Khuskia oryzae

    go.drugbank.com/drugs/DB10581
    Approved

    Khuskia oryzae is a fungus which can provoke allergic reactions. Khuskia oryzae extract is used in allergenic testing.

    Mixtures: Treatment Set TS128871
  10. Drug

    Trichothecium roseum

    go.drugbank.com/drugs/DB10696
    Approved

    Trichothecium roseum is a fungus which can provoke allergic reactions. Trichothecium roseum extract is used in allergenic testing.

    Mixtures: Treatment Set TS128871